The RAPID study was a randomized, double-blind, placebo-controlled, phase 3 study designed to evaluate the efficacy and safety of CARDAMYST™ (etripamil) nasal spray in patients with a history of PSVT¹

Chart showing phase 3 RAPID study design to evaluate the efficacy and safety of CARDAMYST™ (etripamil) nasal spray in patients with a history of PSVT.

Prior to randomization, patients underwent a supervised safety screening and received 2 test doses of CARDAMYST 70 mg delivered 10 minutes apart. Patients were excluded if they could not tolerate the regimen, experienced significant hypotension, or developed prespecified cardiac events (eg, atrioventricular [AV] block, severe bradycardia, significant arrhythmias). Nearly all patients (98.7%, 697/706) tolerated the test dose regimen.^2,3

Patients self-administered CARDAMYST 70 mg intranasally upon experiencing symptoms of PSVT, and a second 70-mg dose was administered if symptoms persisted 10 minutes after the first dose.¹

The primary endpoint was time to conversion of confirmed PSVT to sinus rhythm within 30 minutes of the first dose¹^†

*Use of wearable ECG devices is not required prior to administration of CARDAMYST.¹

†All electrocardiograms (ECGs) were blindly adjudicated by an independent committee of cardiac electrophysiologists who verified that the presenting rhythm was PSVT and that conversion to sinus rhythm persisted for at least 30 seconds. In the RAPID study, 184 out of 255 episodes (72%) were confirmed to be AV nodal-dependent PSVT and used in the primary analysis.^1,2

Key inclusion criteria³

≥18 years of age
ECG-documented diagnosis of PSVT
PSVT episodes ≥20 minutes
Patients who had undergone ablation were eligible as long as they had ECG evidence of PSVT post-ablation